December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

27.87 -0.88 (-3.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
Why Did TVTX Stock Crash 30% In Pre-Market Today? ↗
Via Stocktwits
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Technical and Fundamental Momentum for Growth Investors ↗
Via Chartmill
News headline image
Earnings Scheduled For October 30, 2025 ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments. 
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments. 
Via The Motley Fool
News headline image
Why Travere Therapeutics Stock Got Trounced on Tuesday ↗
A regulatory decision on a top investigational drug won't be coming as soon as hoped. 
Via The Motley Fool
News headline image
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari... 
Via MarketMinute
News headline image
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April ↗
According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. 
Via Stocktwits
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday ↗
Two analysts waxed bullish on the future of the company. 
Via The Motley Fool
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors ↗
Travere Therapeutics (TVTX) shows strong earnings momentum, a bullish technical uptrend, and a current consolidation phase, presenting a potential breakout setup for growth investors. 
Via Chartmill
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup ↗
Travere Therapeutics (TVTX) shows strong high-growth momentum with surging sales and a positive technical setup, signaling a potential breakout. 
Via Chartmill
News headline image
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year ↗
Shares of Ligand Pharmaceuticals are absolutely flying as investors line up behind the company's unique royalty-based model. 
Via Investor's Business Daily
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
Via The Motley Fool
News headline image
Ligand Pharmaceuticals Soars to New Heights: A Deep Dive into its 52-Week High
San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025.... 
Via MarketMinute
Topics Intellectual Property
News headline image
Top 2% Travere Looks To Top Buy Zone After Screaming Up Another Beat ↗
The stock popped Friday — poising itself to top a buy zone — on another sales beat from its linchpin drug. 
Via Investor's Business Daily
Topics Earnings
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Q3 2025 Earnings Soar, Fueled by FILSPARI Sales and Milestone Payments ↗
Travere Therapeutics (TVTX) Q3 2025 earnings crush expectations, driven by strong FILSPARI sales. Revenue soared 160% year-over-year, sparking an 11.7% stock surge. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Novartis Strengthens Kidney Disease Pipeline With Promising Data ↗
Novartis' Fabhalta showed significant efficacy and safety in a Phase 3 IgA nephropathy study, supporting regulatory filings planned for 2026. 
Via Benzinga
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Growth Momentum and Technical Setup ↗
Travere Therapeutics (TVTX) shows strong growth momentum with accelerating earnings and revenue. Its high technical rating and clear setup pattern offer a compelling investment case. 
Via Chartmill
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
The Analyst Verdict: Travere Therapeutics In The Eyes Of 9 Experts ↗
 
Via Benzinga
News headline image
Travere Shares Are Trading Higher Wednesday: What's Going On? ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.